Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 2,086 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: HIV-1 Infection
Interventions: ART, DOR/ISL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Los Angeles, California • Palm Springs, California • San Francisco, California + 12 more

Conditions: Articular Cartilage Disorder of Knee, Articular Cartilage; Degeneration
Interventions: Autologous peripheral blood stem cells and hyaluronic acid, Hyaluronic acid; Biological · Other
Lead sponsor: KLSMC Stem Cells, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Gulf Breeze, Florida

Conditions: Pyoderma Gangrenosum
Interventions: gevokizumab; Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 31
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Oceanside, California + 28 more

Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions: Maralixibat; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 31
States / cities: Phoenix, Arizona • San Diego, California • Palm Harbor, Florida + 28 more

Conditions: Cutaneous Lichen Planus
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more

Conditions: Schizophrenia
Interventions: PERSERIS, Risperidone; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Secondary Hyperparathyroidism, End Stage Kidney Disease
Interventions: PLS240, Placebo, Open-Label Extension PLS240; Drug
Lead sponsor: Pathalys Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 50
States / cities: Anaheim, California • Chula Vista, California • Escondido, California + 43 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 11
States / cities: Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more

Conditions: Schizophrenia
Interventions: Ziprasidone oral capsules; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 18 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more

Conditions: Peanut Allergy, Multi-food Allergy
Interventions: Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 55 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more

Conditions: Fragile X Syndrome
Interventions: arbaclofen; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 5 Years to 50 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 23
States / cities: Phoenix, Arizona • Long Beach, California • Sacramento, California + 20 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: DNL343, Placebo; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 3 more

Conditions: Contraception
Interventions: Radiopaque Etonogestrel (ENG) Implant; Combination Product
Lead sponsor: Organon and Co; Industry
Eligibility: Up to 35 Years · Female only
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more

Conditions: Breast Cancer
Interventions: TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets; Drug
Lead sponsor: Tolmar Inc.; Industry
Eligibility: 18 Years to 51 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 17
States / cities: Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Allogeneic Cardiosphere-Derived Cells (CAP-1002); Biological
Lead sponsor: Capricor Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Gainesville, Florida • Cincinnati, Ohio

Conditions: Acromegaly
Interventions: Debio 4126, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: HIV-1 Infection
Interventions: B/F/TAF, GS-3242, Lenacapavir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 2
States / cities: Ft. Pierce, Florida • Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: KNS-760704; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 19
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more

Conditions: Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions: peginesatide; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 9
States / cities: Pine Bluff, Arkansas • Mountain View, California • Lauderdale Lakes, Florida + 6 more

Conditions: Opiate Dependence
Interventions: very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone; Drug
Lead sponsor: Paolo Mannelli; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypogonadism, Male
Interventions: Testosterone enanthate; Combination Product
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 12 Years to 17 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 22
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 18 more

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: ATYR1940; Biological
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

Efficacy and Safety Study of Intra-Articular Injections of Autologous Peripheral Blood Stem Cells Following Subchondral Drilling Surgery for the Treatment of Articular Cartilage Injury in the Knee

A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

An Open Label Extension Study in Subjects With Fragile X Syndrome

A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels

Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension